Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Arena Pharmarceuticals and Chelsea Therapeutics International Ltd Could Be Today's Biggest Movers in Healthcare

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Good morning, fellow Foolish investors! It's time to check in on the top stories in the health care sector this morning.

Arena gaining momentum?
Shares of obesity drugmaker Arena Pharmaceuticals (NASDAQ: ARNA  ) are up another 3% in premarket trading today following yesterday's 5.27% gain. This latest rally in Arena appears to be driven by a couple of factors. Firstly, Arena recently submitted a marketing application for Belviq in Brazil as a treatment for chronic weight management. Secondly, Belviq saw slightly improving prescription numbers in the U.S. last week. And perhaps most importantly, Arena Pharmaceuticals and its marketing partner Eisai (NASDAQOTH: ESALY) have successfully convinced CVS Caremark and Aetna to include the drug in their coverage, which could provide a major boost to sales going forward.  

Should you join the party? Taking a long-term view, I think it's best to stay on the sidelines for now. Arena and Eisai still have a ways to go to make Belviq a major revenue generator, and there's no way of knowing how Orexigen Therapeutic's (NASDAQ: OREX  ) Contrave will affect Belviq sales, if the drug gains approval later this year.

That said, I like the fact that things are unfolding according to Eisai's marketing plan stated awhile back, showing the two companies are dedicated to overcoming the significant hurdles associated with marketing an obesity drug. So, stay tuned!

Chelsea hopes for a sweet Valentine's gift from the FDA
Perhaps one of the most watched stories in health care today will be Chelsea Therapeutics (NASDAQ: CHTP  ) and the forthcoming regulatory decision for its experimental drug Northera, indicated as a treatment for neurogenic orthostatic hypotension. Northera previously received a strong endorsement from the FDA Advisory Committee, but the FDA reviewer appeared to be less than enthusiastic about the drug's clinical trials. So, there is still an inkling of doubt about the drug's approval today, despite a 16 to 1 'yes' vote from the Advisory Committee. 

Investors are also concerned that the drug's label could limit its use to 1-2 weeks, or the FDA could require a particularly burdensome postmarketing study requirement. Indeed, there are several unknowns surrounding Chelsea and Northera this morning. And this is why I think it's best to take a pass on Chelsea for the time being.

Even so, I think you should keep Chelsea on your watch list. If the drug is approved today, the company could be dramatically undervalued, depending on how the label turns out. 

Biopharmas like Arena and Chelsea have been strong performers lately, but this stock may be a better pick going forward.
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Read/Post Comments (1) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2839582, ~/Articles/ArticleHandler.aspx, 9/3/2015 1:22:40 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

George Budwell

George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Today's Market

updated Moments ago Sponsored by:
DOW 16,386.46 35.08 0.21%
S&P 500 1,952.40 3.54 0.18%
NASD 4,742.20 -7.78 -0.16%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/3/2015 1:06 PM
ARNA $2.75 Up +0.05 +1.85%
Arena Pharmaceutic… CAPS Rating: **
CHTP $0.00 Down +0.00 +0.00%
Chelsea Therapeuti… CAPS Rating: **
ESALY $66.67 Up +1.78 +2.74%
Eisai Co., Ltd (AD… CAPS Rating: No stars
OREX $2.85 Up +0.11 +3.83%
Orexigen Therapeut… CAPS Rating: **